Invest Securities maintains its buy recommendation on TME Pharma shares, with an unchanged target price of 4.2 euros.

The analyst reports that the company recently published long-awaited 18-month results highlighting the synergy between the 3 treatments (NOX-A12 + radiotherapy + bevacizumab) in a trial.

The company reports that 3 of the 6 patients are still alive at this stage, two of them clinically stable.

The last patient is less stable, but could still reach and exceed the 18-month survival period. If this is the case, then the 18-month survival rate for the study could be 67%, compared with a rate of 5% with standard treatments', stresses the analyst.

TME plans to apply to the FDA this month with a view to a future clinical trial that could be initiated as early as the 1st half of 2024.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.